Cytoplasmic tail of the Receptor for Advanced Glycation End-products and Diaphanous-related formin 1 protein-protein interaction (ctRAGE–DIAPH1 PPI)

The ctRAGE–DIAPH1 protein-protein interaction is a pivotal signaling mechanism involving the binding of the cytoplasmic tail of the Receptor for Advanced Glycation End-products (ctRAGE) to the Diaphanous-related formin 1 (DIAPH1, also known as mDia1). Because RAGE lacks intrinsic kinase activity, its ability to transmit signals into the cell depends entirely on its interaction with DIAPH1, which acts as a scaffold and effector for downstream Rho GTPases like Rac1 and Cdc42 (Manigrasso et al., 2016, Scientific Reports). This signaling axis is hyperactivated in conditions characterized by high levels of RAGE ligands, such as advanced glycation end-products (AGEs) in diabetes or S100 proteins in inflammatory states (Schmidt, 2023, Journal of Clinical Investigation). Dysregulation of the ctRAGE–DIAPH1 interaction contributes significantly to the pathogenesis of diabetic complications, including nephropathy and impaired wound healing, as well as atherosclerosis and tumor metastasis (UniProt Q15109; O60610). Therapeutic strategies focus on small molecule inhibitors that competitively bind to the ctRAGE-binding site on DIAPH1, thereby preventing the formation of the signaling complex. Such inhibitors, like RAGE228, demonstrate potential in reducing inflammation and vascular damage in preclinical models, representing a precise approach to modulating RAGE-mediated disease without interfering with the receptor's extracellular ligand-trapping functions.

Other names

RAGE-DIAPH1 signaling axisctRAGE-mDia1 interactionRAGE-mDia1 complexAGER-DIAPH1 interaction

Competitive inhibition of the binding between the cytoplasmic tail of RAGE (ctRAGE) and the FH1 domain of DIAPH1 to block downstream intracellular signaling.